Incyte (INCY) Asset Writedowns and Impairment (2017)
Incyte (INCY) posted Asset Writedowns and Impairment of $12.0 million for Q3 2017.
Incyte (INCY) Asset Writedowns and Impairment (2017) Analysis & Trends
Incyte's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $12.0 million for Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 12.00 Mn |
| Sep 30, 2017 | 12.00 Mn |